Metoprolol succinate is a long-acting, cardioselective beta-blocker used to treat high blood pressure, heart failure, angina and certain heart rhythm disorders. It is the succinate salt formulation of metoprolol, designed for once-daily dosing via an extended-release mechanism. It is one of the most prescribed cardiovascular medicines in India.

Drug Class: Beta-Blocker - How Metoprolol Slows the Heart

Metoprolol succinate belongs to the class of drugs called beta-adrenoceptor blockers or beta-blockers, which work by blocking the action of adrenaline (epinephrine) and noradrenaline at beta-adrenoceptors throughout the body. Metoprolol is classified as a cardioselective (beta-1 selective) beta-blocker - it preferentially blocks beta-1 receptors in the heart rather than beta-2 receptors in the lungs and blood vessels. This selectivity makes metoprolol safer than non-selective beta-blockers in patients with mild asthma or COPD however it is not completely free of respiratory effects.

Medical Uses

Doctors prescribe metoprolol for:

• Hypertension (high blood pressure): Used as first-line or add-on therapy; reduces blood pressure by lowering heart rate and cardiac output; Indian guidelines (CSI/API) include beta-blockers for hypertension, particularly in patients with coexisting coronary artery disease, heart failure or recent myocardial infarction

• Chronic heart failure: Metoprolol succinate (extended-release) is indicated for stable heart failure with reduced ejection fraction (HFrEF)

• Stable angina pectoris: Reduces the frequency and severity of angina episodes by lowering heart rate and myocardial oxygen demand; a first-line agent for stable angina.

How Metoprolol Succinate Works - Blocking Beta-1 Receptors

Adrenaline and noradrenaline bind to beta-1 receptors in the heart, increasing heart rate, contractility and conduction through the AV node. Metoprolol competitively blocks these receptors, resulting in a lower resting heart rate (typically by 10 to 20 beats per minute), reduced contractility and reduced myocardial oxygen demand. The extended-release mechanism of the succinate formulation ensures gradual, stable drug release over 24 hours, avoiding the peak-and-trough fluctuations seen with immediate-release metoprolol tartrate.

Available Forms and Strengths of Metoprolol Succinate

Metoprolol is available as extended-release tablets in strengths of 12.5 mg, 25 mg, 50 mg, 100 mg and 200 mg. The tablet must be swallowed whole and must never be crushed or chewed as this destroys the extended-release mechanism. However some brands produce scored tablets that can be broken in half along the score line and each half must still be swallowed whole.

How to Take Metoprolol Succinate Correctly

• Once daily dosing: Take at the same time each day, ideally in the morning, with or without food; consistency improves blood level stability

• Never crush or chew: Crushing or chewing releases the full dose at once; scored tablets may be broken in half but each half must be swallowed whole

• Do not stop suddenly: Sudden discontinuation can trigger rebound hypertension, severe angina and acute myocardial infarction in patients with coronary artery disease; the dose must be tapered over at least 1 to 2 weeks under medical supervision.

Dosage and Duration – How Much Metoprolol Succinate to Take

Metoprolol dosage varies and depends on the underlying conditions:

• Hypertension: 25 to 50 mg once daily; maintenance 50 to 200 mg once daily depending on blood pressure response

• Chronic heart failure (HFrEF): Start at 12.5 to 25 mg once daily; double the dose every 2 weeks as tolerated, up to 200 mg once daily; titration must be slow and supervised

• Stable angina: 50 to 200 mg once daily; adjust to achieve a resting heart rate of 55 to 60 beats per minute

• Elderly patients: Start at 12.5 mg or 25 mg and titrate slowly; elderly patients are more sensitive to hypotension and bradycardia.

Common and Serious Side Effects

Common side effects are:

• Fatigue and lethargy

• Bradycardia (slow heart rate)

• Cold extremities 

• Dizziness and light-headedness (orthostatic hypotension) particularly on standing

• Sleep disturbance and vivid dreams 

Serious side effects are:

• Severe bradycardia or heart block: May require dose reduction or discontinuation

• Bronchospasm: Metoprolol can still cause bronchospasm in patients with severe asthma or COPD particularly at higher doses; avoid in severe reactive airways disease.

Precautions: Who Should Use Metoprolol Succinate with Caution?

Certain people should take metoprolol with caution. They are:

• Patients with asthma or COPD: Cardioselectivity reduces but does not eliminate bronchospasm risk; use with extreme caution only when cardiovascular benefit clearly outweighs the respiratory risk; avoid in severe asthma

• Patients with diabetes mellitus: Metoprolol can mask tachycardia (a warning sign of hypoglycaemia) and prolong hypoglycaemic episodes; monitor blood glucose more carefully

• Patients with AV block: Use with caution in first-degree or second-degree AV block; contraindicated in third-degree AV block

• Patients with phaeochromocytoma: Metoprolol must never be given alone; unopposed alpha-receptor stimulation causes severe hypertension; an alpha-blocker must be given first.

Drug Interactions and Important Safety Considerations

Main interactions are:

• Calcium channel blockers (verapamil, diltiazem): Combining with rate-limiting calcium channel blockers can cause severe bradycardia, AV block, and cardiac arrest; use with extreme caution under specialist supervision

• Digoxin: Both drugs slow AV nodal conduction; concurrent use increases the risk of AV block and bradycardia

• Antihypertensive drugs: Additive blood pressure-lowering effects requiring dose adjustments; particularly relevant in India where polypharmacy for hypertension is common

• NSAIDs (ibuprofen, diclofenac): Reduce the antihypertensive effect of metoprolol by promoting sodium retention; avoid regular NSAID use in patients on metoprolol for hypertension.

Metoprolol Succinate vs Metoprolol Tartrate 

Key differences are:

• Salt and release profile: Metoprolol succinate is an extended-release (XL/XR) formulation for once-daily dosing; metoprolol tartrate is an immediate-release formulation given two to three times daily, with peak-and-trough blood level fluctuations

• Cardiovascular outcomes: Metoprolol succinate extended-release is the formulation proven in the MERIT-HF trial to reduce mortality in heart failure; immediate-release metoprolol tartrate does not have this specific heart failure indication.

FAQs

1. What is metoprolol succinate used for?

   Metoprolol succinate is used to treat high blood pressure, chronic heart failure with reduced ejection fraction, stable angina, heart rhythm disorders (atrial fibrillation, supraventricular tachycardia) and to reduce the risk of reinfarction after a heart attack. 

2. What is the difference between metoprolol succinate and metoprolol tartrate?

   Metoprolol succinate is an extended-release (once-daily) formulation whereas metoprolol tartrate is an immediate-release formulation given two to three times daily with significant blood level fluctuations. Metoprolol succinate is the formulation proven to reduce mortality in chronic heart failure (MERIT-HF trial). Metoprolol tartrate is less expensive and more commonly used in acute hospital settings.

3. Can patients with asthma use metoprolol?

   Metoprolol is cardioselective - it preferentially blocks beta-1 receptors in the heart rather than beta-2 receptors in the lungs, making it relatively safer in patients with mild or moderate asthma. Cardioselectivity is not absolute as at higher doses, metoprolol can still cause bronchospasm. It should be used with extreme caution in asthma patients and should be avoided in severe asthma or uncontrolled COPD.

4. Does metoprolol cause weight gain?

   Weight gain of 1 to 2 kg is a recognised side effect of metoprolol and other beta-blockers more common in the first few months. The mechanism involves reduced metabolic rate, fluid retention and in some patients, increased appetite. This weight gain is usually modest and is not a reason to stop the medicine.

5. Can metoprolol affect sleep and cause vivid dreams?

   Yes metoprolol can cause sleep disturbance, nightmares and vivid or disturbing dreams because it is more lipophilic (fat-soluble) than beta-blockers and crosses the blood-brain barrier more readily. If sleep disturbance is troublesome, taking the tablet in the morning rather than at night may help.

6. Is metoprolol safe for patients with diabetes?

   Metoprolol can be used in patients with diabetes but requires careful monitoring. It blunts tachycardia as a warning sign of low blood sugar (though sweating is preserved) and can prolong hypoglycaemic episodes by reducing the counter-regulatory response. Blood glucose should be monitored more carefully; the risk is greatest in patients on insulin or sulphonylureas.

7. What happens if metoprolol is stopped suddenly?

   Stopping metoprolol suddenly can cause a dangerous rebound effect. The beta receptors in the heart become hypersensitive to adrenaline and noradrenaline, causing rebound hypertension, severe angina and in patients with coronary artery disease, acute myocardial infarction. Metoprolol must always be tapered gradually over 1 to 2 weeks under medical supervision.

8. Can metoprolol cause depression or low mood?

   Depression and low mood have been reported as side effects of metoprolol and other beta-blockers. The most likely mechanism is metoprolol's penetration of the blood-brain barrier, affecting central noradrenergic and dopaminergic pathways. The effect appears to be more common with lipophilic beta-blockers (metoprolol, propranolol) than with hydrophilic ones (atenolol).

9. How long does it take for metoprolol to lower blood pressure?

   Metoprolol begins to lower blood pressure within hours of the first dose but the full antihypertensive effect typically takes 1 to 2 weeks. If blood pressure remains inadequately controlled after 4 weeks at the target dose an additional antihypertensive agent is typically added; combination with an ACE inhibitor (enalapril, ramipril) or a calcium channel blocker (amlodipine) is common.

10. Is metoprolol the same as atenolol?

    No metoprolol and atenolol are both cardioselective beta-blockers but are distinct drugs. Atenolol is hydrophilic (water-soluble) and does not cross the blood-brain barrier significantly, causing fewer sleep disturbances, vivid dreams and mood side effects than metoprolol. 

References

1. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7. https://doi.org/10.1016/S0140-6736(99)04440-2

2. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200):1730–7. https://doi.org/10.1136/bmj.318.7200.1730

3. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52(18):1482–9. https://doi.org/10.1016/j.jacc.2008.06.048

4. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). JAMA. 2003;289(19):2560–72. https://doi.org/10.1001/jama.289.19.2560

5. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–8. https://doi.org/10.1056/NEJM200105313442201